BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs 2021;:1-9. [PMID: 34429006 DOI: 10.1080/13543784.2021.1972969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Simón Serrano S, Tavecchio M, Mallik J, Grönberg A, Elmér E, Kifagi C, Gallay P, Hansson MJ, Massoumi R. Synergistic Effects of Sanglifehrin-Based Cyclophilin Inhibitor NV651 with Cisplatin in Hepatocellular Carcinoma. Cancers 2022;14:4553. [DOI: 10.3390/cancers14194553] [Reference Citation Analysis]
2 Chen M, Jiang M, Wang X, Shen L, Li J. Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors. Expert Opin Biol Ther 2022. [PMID: 36124972 DOI: 10.1080/14712598.2022.2125799] [Reference Citation Analysis]
3 Franses JW, Lim M, Burgoyne AM, Mody K, Lennerz J, Chang J, Imperial R, Dybel SN, Dinh TM, Masannat J, Weipert CM, Hsiehchen D. Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma. The Oncologist 2022. [DOI: 10.1093/oncolo/oyac189] [Reference Citation Analysis]
4 Glantzounis GK, Korkolis D, Sotiropoulos GC, Tzimas G, Karampa A, Paliouras A, Asimakopoulos AG, Davakis S, Papalampros A, Moris D, Felekouras E. Individualized Approach in the Surgical Management of Hepatocellular Carcinoma: Results from a Greek Multicentre Study. Cancers (Basel) 2022;14:4387. [PMID: 36139548 DOI: 10.3390/cancers14184387] [Reference Citation Analysis]
5 Xie Q, Zhang P, Wang Y, Mei W, Zeng C. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Front Oncol 2022;12:958720. [DOI: 10.3389/fonc.2022.958720] [Reference Citation Analysis]
6 Jia M, Jia J, Xu J, Xue H. . CMAR 2022;Volume 14:2625-38. [DOI: 10.2147/cmar.s372125] [Reference Citation Analysis]
7 Li D, Xu L, Ji J, Bao D, Hu J, Qian Y, Zhou Y, Chen Z, Li D, Li X, Zhang X, Wang H, Yi C, Shi M, Pang Y, Liu S, Xu X. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study. Front Immunol 2022;13:944062. [DOI: 10.3389/fimmu.2022.944062] [Reference Citation Analysis]
8 Carloni R, Rizzo A, Cusmai A, Palloni A, Federico AD, Marco MD, Massafra R, Fanizzi A, Palmiotti G, Brandi G. Advances in novel systemic therapies for advanced hepatocellular carcinoma. Future Med Chem 2022. [PMID: 35997677 DOI: 10.4155/fmc-2022-0045] [Reference Citation Analysis]
9 Zhang L, Chen C, Chai D, Li C, Guan Y, Liu L, Kuang T, Deng W, Wang W. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors. Front Immunol 2022;13:956533. [DOI: 10.3389/fimmu.2022.956533] [Reference Citation Analysis]
10 Wu QQ, Chen YX, Du SS, Hu Y, Yang P, Sun J, Wang XY, Wu WX, Zhang SM, Zeng ZC. Effect of the normal liver mean dose on intrahepatic recurrence in patients with hepatocellular carcinoma after receiving liver stereotactic body radiation therapy. Transl Oncol 2022;25:101492. [PMID: 35944415 DOI: 10.1016/j.tranon.2022.101492] [Reference Citation Analysis]
11 Xin Y, Cao F, Yang H, Zhang X, Chen Y, Cao X, Zhou X, Li X, Zhou J. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Front Immunol 2022;13:929141. [DOI: 10.3389/fimmu.2022.929141] [Reference Citation Analysis]
12 Liu J, Shi Y, Liu X, Zhang D, Zhang H, Chen M, Xu Y, Zhao J, Zhong W, Wang M. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus. Transl Oncol 2022;24:101473. [PMID: 35905639 DOI: 10.1016/j.tranon.2022.101473] [Reference Citation Analysis]
13 Zhao Z, Chen Z, Yu B, Xiao B, Liu L, Xia Y, Li A, Wang P, Xiang C, Liu C, Yang H, Li H, Xiao T. Characterization of the immune cell infiltration landscape in myxofibrosarcoma to aid immunotherapy. Front Immunol 2022;13:916915. [DOI: 10.3389/fimmu.2022.916915] [Reference Citation Analysis]
14 Suzuki H, Iwamoto H, Shimose S, Niizeki T, Shirono T, Noda Y, Kamachi N, Yamaguchi T, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review. Front Oncol 2022;12:948293. [DOI: 10.3389/fonc.2022.948293] [Reference Citation Analysis]
15 Jing N, Wang L, Zhuang H, Ai C, Jiang G, Liu Z, Wang R. Sex-Biased Immune Responses to Antibiotics during Anti-PD-L1 Treatment in Mice with Colon Cancer. Journal of Immunology Research 2022;2022:1-26. [DOI: 10.1155/2022/9202491] [Reference Citation Analysis]
16 Liu J, Ma J, Xing N, Ji Z, Li J, Zhang S, Guo Z. Interferon-γ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04201-z] [Reference Citation Analysis]
17 Orrapin S, Udomruk S, Lapisatepun W, Moonmuang S, Phanphaisarn A, Phinyo P, Pruksakorn D, Chaiyawat P. Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review. Cancers 2022;14:3373. [DOI: 10.3390/cancers14143373] [Reference Citation Analysis]
18 Long X, Zhang L, Wang WQ, Zhang EL, Lv X, Huang ZY. Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review. Onco Targets Ther 2022;15:703-16. [PMID: 35791424 DOI: 10.2147/OTT.S365652] [Reference Citation Analysis]
19 Rizzo A. Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities. J Clin Med 2022;11:3912. [PMID: 35807197 DOI: 10.3390/jcm11133912] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Ding ZN, Meng GX, Xue JS, Yan LJ, Liu H, Yan YC, Chen ZQ, Hong JG, Wang DX, Dong ZR, Li T. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis. J Cancer Res Clin Oncol 2022. [PMID: 35767193 DOI: 10.1007/s00432-022-04133-8] [Reference Citation Analysis]
21 Chen Y, Hu H, Yuan X, Fan X, Zhang C. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Front Immunol 2022;13:896752. [PMID: 35757756 DOI: 10.3389/fimmu.2022.896752] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhang Q, Li Q, Shang F, Li G, Wang M. The Benefits of Radical Treatments with Synchronous Splenectomy for Patients with Hepatocellular Carcinoma and Portal Hypertension. Cancers 2022;14:3155. [DOI: 10.3390/cancers14133155] [Reference Citation Analysis]
23 Li L, Yang S, Chen Y, Tian L, He Y, Wu B, Dong D. Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis. Front Pharmacol 2022;13:891008. [PMID: 35721168 DOI: 10.3389/fphar.2022.891008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Huang ZL, Xu B, Li TT, Xu YH, Huang XY, Huang XY. Integrative Analysis Identifies Cell-Type-Specific Genes Within Tumor Microenvironment as Prognostic Indicators in Hepatocellular Carcinoma. Front Oncol 2022;12:878923. [PMID: 35707353 DOI: 10.3389/fonc.2022.878923] [Reference Citation Analysis]
25 Koustas E, Trifylli EM, Sarantis P, Papadopoulos N, Karapedi E, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Papavassiliou KA, Karamouzis MV, Papavassiliou AG. Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives. Int J Mol Sci 2022;23:6664. [PMID: 35743107 DOI: 10.3390/ijms23126664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kobeissi JM, Hilal L, Simone CB 2nd, Lin H, Crane CH, Hajj C. Proton Therapy in the Management of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:2900. [PMID: 35740567 DOI: 10.3390/cancers14122900] [Reference Citation Analysis]
27 Rizzo A, Cusmai A, Massafra R, Bove S, Comes MC, Fanizzi A, Rinaldi L, Acquafredda S, Gadaleta-Caldarola G, Oreste D, Zito A, Giotta F, Lorusso V, Palmiotti G. Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis. Cells 2022;11:1857. [PMID: 35740985 DOI: 10.3390/cells11121857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Rizzo A, Palmiotti G. Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block? Immunotherapy 2022. [PMID: 35642433 DOI: 10.2217/imt-2022-0021] [Reference Citation Analysis]
29 Lachiondo-ortega S, Delgado TC, Baños-jaime B, Velázquez-cruz A, Díaz-moreno I, Martínez-chantar ML. Hu Antigen R (HuR) Protein Structure, Function and Regulation in Hepatobiliary Tumors. Cancers 2022;14:2666. [DOI: 10.3390/cancers14112666] [Reference Citation Analysis]
30 Kavec MJ, Urbanova M, Makovicky P, Opattová A, Tomasova K, Kroupa M, Kostovcikova K, Siskova A, Navvabi N, Schneiderova M, Vymetalkova V, Vodickova L, Vodicka P. Oxidative Damage in Sporadic Colorectal Cancer: Molecular Mapping of Base Excision Repair Glycosylases MUTYH and hOGG1 in Colorectal Cancer Patients. Int J Mol Sci 2022;23:5704. [PMID: 35628513 DOI: 10.3390/ijms23105704] [Reference Citation Analysis]
31 Hatzidakis A, Müller L, Krokidis M, Kloeckner R. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers (Basel) 2022;14:2469. [PMID: 35626073 DOI: 10.3390/cancers14102469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Rizzo A, Cusmai A, Gadaleta-caldarola G, Palmiotti G. Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward. Medicina 2022;58:600. [DOI: 10.3390/medicina58050600] [Reference Citation Analysis]
33 Ning B, Liu Y, Wang M, Li Y, Xu T, Wei Y. The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis. Front Pharmacol 2022;13:748674. [PMID: 35355708 DOI: 10.3389/fphar.2022.748674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Tang S, Qin C, Hu H, Liu T, He Y, Guo H, Yan H, Zhang J, Tang S, Zhou H. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells 2022;11:320. [DOI: 10.3390/cells11030320] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
35 Rizzo A, Ricci AD, Di Federico A, Frega G, Palloni A, Tavolari S, Brandi G. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand? Front Oncol 2021;11:803133. [PMID: 34976841 DOI: 10.3389/fonc.2021.803133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Qin Y, Li M, Lin Q, Pan X, Liang Y, Huang Z, Liu Z, Huang L, Fang M. Colorectal Cancer Cell Differentiation Trajectory Predicts Patient Immunotherapy Response and Prognosis. Cancer Control 2022;29:10732748221121382. [PMID: 36036380 DOI: 10.1177/10732748221121382] [Reference Citation Analysis]
37 Qu C, Ma T, Yan X, Li X, Li Y; Lanzhou University Second Hospital, Lanzhou 730030, China, Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou 730030, China. . MBE 2022;19:3069-90. [DOI: 10.3934/mbe.2022142] [Reference Citation Analysis]
38 Zhang N, Li P, Wu X, Xia S, Zhao X, Chen L. Analysis of Threshold Changes of Tumor Mutation Burden of Gastric Cancer and Its Relationship with Patients' Prognosis. J Oncol 2021;2021:9026610. [PMID: 34616454 DOI: 10.1155/2021/9026610] [Reference Citation Analysis]